ADMA Biologics Inc $ADMA Shares Sold by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System reduced its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 51.1% during the third quarter, Holdings Channel reports. The firm owned 34,306 shares of the biotechnology company’s stock after selling 35,854 shares during the period. Maryland State Retirement & Pension System’s holdings in ADMA Biologics were worth $503,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ADMA. Salomon & Ludwin LLC bought a new position in shares of ADMA Biologics in the third quarter valued at $25,000. Cullen Frost Bankers Inc. boosted its stake in shares of ADMA Biologics by 112.5% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,081 shares in the last quarter. Financial Consulate Inc. acquired a new position in shares of ADMA Biologics in the 3rd quarter worth $44,000. Ameritas Advisory Services LLC acquired a new stake in shares of ADMA Biologics during the second quarter worth $46,000. Finally, Blue Trust Inc. raised its position in shares of ADMA Biologics by 53.6% during the second quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 964 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $17.40 on Friday. The company’s fifty day moving average is $18.47 and its two-hundred day moving average is $17.10. The company has a market cap of $4.14 billion, a P/E ratio of 20.23 and a beta of 0.47. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. During the same quarter last year, the firm posted $0.15 earnings per share. ADMA Biologics’s revenue was up 12.0% compared to the same quarter last year. Equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.